Lara A Dunn Selected Research

Lara A Dunn Research Topics

9	Neoplasms (Cancer) 04/2022 - 01/2018
6	Squamous Cell Carcinoma of Head and Neck 04/2022 - 11/2016
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 01/2018
3	Thyroid Neoplasms (Thyroid Cancer) 01/2019 - 11/2017
2	Neoplasm Metastasis (Metastasis) 01/2021 - 11/2017
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 01/2020
2	Necrosis 01/2020 - 01/2020
2	Stomatitis 01/2020 - 11/2017
1	Nasopharyngeal Carcinoma 01/2021
1	Deglutition Disorders (Dysphagia) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Neutropenia 01/2021
1	Oropharyngeal Neoplasms 01/2021
1	Respiratory Insufficiency (Respiratory Failure) 01/2021
1	Rupture 01/2021
1	Facial Pain (Myofacial Pain) 01/2020
1	Osteoradionecrosis 01/2020
1	Merkel Cell Carcinoma 01/2020
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2018
1	Body Weight (Weight, Body) 01/2018
1	Hyperglycemia 11/2017
1	Anemia 11/2017
1	Fatigue 11/2017
1	Carcinoma (Carcinomatosis) 11/2017

2	Immune Checkpoint InhibitorsIBA 04/2022 - 01/2018
2	cemiplimabIBA 01/2020 - 01/2018
2	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2018
2	IodineIBA 01/2019 - 11/2017
1	avelumabIBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	AlpelisibIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	PlatinumIBA 01/2020
1	NivolumabIBA 01/2020
1	Radiation-Sensitizing AgentsIBA 01/2020
1	Cetuximab (Erbitux)FDA Link 01/2020
1	Thyroglobulin FDA Link 01/2019
1	VemurafenibIBA 01/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	Tyrosine Kinase InhibitorsIBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	afliberceptIBA 01/2019
1	Oncogene Proteins (Oncogene Protein)IBA 01/2018
1	AfatinibIBA 01/2018
1	Carboplatin (JM8)FDA LinkGeneric 01/2018
1	Ribavirin (Virazole)FDA LinkGeneric 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Phosphotransferases (Kinase)IBA 11/2017
1	temsirolimus FDA Link 11/2017
1	Sorafenib (BAY 43-9006)FDA Link 11/2017

5	Radiotherapy 01/2021 - 11/2017
3	Therapeutics 04/2022 - 11/2017
3	Drug Therapy (Chemotherapy) 04/2022 - 11/2017
3	Proton Therapy 01/2021 - 01/2020
2	Immunotherapy 04/2022 - 11/2016
2	Chemoradiotherapy 01/2021 - 11/2017
1	Neoadjuvant Therapy 04/2022
1	Retreatment 01/2020
1	Drug Tapering 01/2020
1	Re-Irradiation 01/2020
1	Induction Chemotherapy 01/2018
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 11/2017